Neurogene (NASDAQ:NGNE) Sees Strong Trading Volume - Still a Buy?Market Beat·Aug 24 at 12:00 PMNGNE-2.35%
Neurogene (NASDAQ:NGNE) Posts Earnings Results, Misses Expectations By $0.11 EPSMarket Beat·Aug 11 at 08:56 AMNGNE-2.35%
Neurogene publishes corporate presentation highlighting NGN-401 gene therapy program for Rett syndromePUBT·Aug 11 at 06:43 AMNGNE-2.35%
Neurogene President, CFO Christine Mikail Cvijic sells 4,800 shares for $173,468.40PUBT·Jul 7 at 08:09 PMNGNE-2.35%
Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study DesignTip Ranks·Jul 7 at 10:45 AMNGNE-2.35%
Neurogene grants inducement stock options for 96,450 shares to new employeesPUBT·Jul 6 at 03:01 PMNGNE-2.35%
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NGNE Stock NewsStockTitan·Jul 6 at 07:01 AMNGNE-2.35%
Neurogene President, CFO Christine Mikail Cvijic sells 4,800 common shares for $166,407.28PUBT·Jul 2 at 05:43 PMNGNE-2.35%
Neurogene says cash runway extends into Q1 2029 after USD 134.8 million stock offeringPUBT·Jul 2 at 05:04 AMNGNE-2.35%
